摘要
目的 评价注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白（rhTNFR：Fc）对强直性脊柱炎患者血清ESR及CRP的影响研究。方法 选取2013年10月~2015年10月宁波市北仑区人民医院收治的48例强直性脊柱炎患者,随机分为对照组和试验组,各24例;对照组给予柳氮磺吡啶肠溶片口服,1.0 g/次,bid;试验组给予rh TNFR：Fc皮下注射,25 mg/次,2次/周。比较2组患者治疗前后红细胞沉降率（ESR）、血清C反应蛋白（CRP）水平,治疗有效率及安全性。结果 治疗后,与对照组比较,试验组患者ESR及血清CRP水平较低（P〈0.05）。试验组的治疗有效率为95.84%,显著高于对照组75.00%（P〈0.05）。2组患者不良反应发生率比较差异无统计学意义。结论 rhTNFR：Fc能够明显降低强直性脊柱炎患者的ESR及血清CRP水平,改善临床症状,临床疗效好及安全性较高。
Objective To evaluate the research of Recombinant Human Tumor Necrosis Factor-αReceptorⅡ：IgG Fc Fusion Protein for Injection in the treatment of patients with ankylosing spondylitis in serum ESR and CRP.Methods 48 cases of patients with ankylosing spondylitis from October 2013 to October 2015 in our hospitol were randomly divided into the control group and treatment group , 24 cases in each group.The control group was treated with sulfasalazine enteric-coated Tablets orally, 1.0 g/time,bid;the experimental group was treated with rhTNFR：Fc for subcutaneous injection, 25 mg/time, two times/week.erythrocyte sedimentation rate （ESR）, serum C reactive protein （CRP） level, efficiency of treatment and safety of two groups were compared before and after treatment.Results After treatment, compared with the control group, the ESR and the serum level of CRP were lower in the experimental group （P〈0.05）; the treatment efficiency of the experimental group 95.84% was significantly higher than that of the control group 75.00% （P〈0.05）.There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion The rhTNFR：Fc can significantly reduce the ESR and the serum level of CRP in patients with ankylosing spondylitis, improve clinical symptoms,the clinical efficacy and safety were high.
出处
《中国生化药物杂志》
CAS
2017年第3期92-94,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白
强制性脊柱炎
临床疗效
安全性
recombinant human tumor necrosis factor-αreceptorⅡ： IgG fc fusion protein for injection
ankylosing spondylitis
clinical efficacy
safety
